Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-072232
Filing Date
2025-05-15
Accepted
2025-05-15 12:14:52
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 15324
2 EX-99.A ck0001910592-ex99_a.htm EX-99.A 15886
  Complete submission text file 0000950170-25-072232.txt   33099
Mailing Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791
Business Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791 561-704-8527
Aspire Biopharma Holdings, Inc. (Subject) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-93583 | Film No.: 25950523
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 299 PARK AVE 21ST FLOOR NEW YORK NY 10171
Business Address 299 PARK AVE 21ST FLOOR NEW YORK NY 10171 212 832 4111
Harraden Circle Investments, LLC (Filed by) CIK: 0001910592 (see all company filings)

EIN.: 813057945 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A